Showing posts with label stem cells. Show all posts
Showing posts with label stem cells. Show all posts

Tuesday, February 15, 2011

Reversibility: Dollo's 'law' in development and evolution

We recently posted on reports of the re-evolution of traits that had long been lost in evolutionary time.  This seemed to violate Dollo's "law" that evolution was a one-way train that couldn't back up.

When there are people in a population with or without a particular trait, say, eye color, and their children have a different version, we are not perplexed. Contingencies of gene expression or genotype or alleles (genetic variants) in the population can make this happen.  Darwin tried to fit his idea of inheritance with these ideas, mainly by hand-waving.  Now armed with concepts like multi-gene control and recessiveness of alleles, we have no problem understanding how these things happen.

But there are reasons to think that true reversibility of complex traits can't often happen over evolutionary time.  The basis of the argument is that too many genetic changes are required for a complex trait to be constructed and if the trait is 'erased' by mutation (and that is supported in the face of selection), then over time too many other genetic changes (mutations, gene duplications, other uses of genes, etc.) will make it impossible to back-track.

From this point of view, the 'new' version of the trait is physically similar to the old, or to that in a widely distant species, but is due to selection for the same trait that happens to pick up different genes and alleles to get the job done.  But if a pathway has been conserved because it's used for other things in the organism, it may be that simple genetic changes can reactivate that pathway in a context in which it was active long ago.

There has been a similar kind of no-going-back dogma, a kind of Dollo's "law" in developmental genetics.  Stem cells can differentiate into anything, but once that happens, the differentiated cells simply cannot go back to being stem cells.  We now know that this is not accurate. Even a small number of genetic changes in experimental systems can restore various stem-cell states.  This can happen even if the cell being manipulated is highly differentiated.  Is this as surprising or inexplicable as reversals in evolution?

The answer is that it is far less surprising, as a generality.  With some few notable exceptions, all the cells in your body have the same genome. This means that while each cell is of a particular type largely because it uses a specific set, but not all, of the genes in the genome.  There are, so to speak, 'blood' genes, 'stomach' genes, and so on. Gene expression is based on the physical packaging of chromosome regions and the presence of proteins specific to the cell type, that bind to DNA in regions near to, and that cause the expression of the specifically used genes.  But since with few exceptions all the genes still exist in all cells, if one changed these regulatory traits (packaging and so on of DNA, presence of regulatory proteins), one could make the cell do something else.  There may be too many changes in expression needed to make a stomach cell into a lung or muscle cell on its own, but we're looking at cells from the outside, and cells can be engineered to redifferentiate or dedifferentiate by experimentally imposing required sets of change. And in a sense it's why in some instances it only takes about 4 genes being manipulated to bring cells back to a very primitive stem cell type of state.

Evolution is different,  because once a species is committed to a particular direction, its genes themselves as well as their usage have changed, by virtue of mutation and frequency change induced by chance or natural selection.  Thus, spiders and grasshoppers no longer have the same genes so that only the expression pattern would need to be changed to let spiders hop or grasshoppers spin webs.  That is why evolution rarely truly reverses. Sometimes only a few changes would be needed, if basic pathways still exist but have been mutationally inactivated.

On the other hand, most traits have many paths and most genes have many uses, so that there can be many different paths by which some absent trait--or its likeness!--can reappear.  Natural selection and chance could activate some suitable set of genes to make this happen, and how likely it is depends on what environmental constraints are.  And since many developmental genes are highly conserved over long time periods, there can easily be similarities in the genetic basis of reappearance.

We know that some traits, such as complete vs incomplete metamorphosis in some species of amphibians (i.e., whether or not they go through a larval stage), or the pattern of ocelli (middle eyes) in insects, have re-evolved.  And we know that some genes from mammals can induce similar effects even in insects, by replacing or over activating their corresponding insect gene.

So, reversals are of many types due to many causes.  How likely they are, and how genetically they are brought about, are statistical and context-specific questions.  But there are no real mysteries about whether or not they are possible.

Tuesday, September 7, 2010

The Gospel of St Francis....Collins, that is

The Sept 6 New Yorker has a story about Francis Collins, head of the National Institutes of Health -- his life, his religion, and how he thought he had resolved the debate over the use of embryonic stem cells.  He is, as everyone knows, a born-again evangelical Christian, so naturally people wondered where he would come down on this issue. He's often treated as if his word is Gospel when it comes to health; but he's not Catholic so he's not St Francis.

Indeed, people wondered how he'd come down on many issues, given his religious bent, but he assured us that this job was separate from his religion (he was quoted in the New York Times at the time of his nomination as saying, “I have made it clear that I have no religious agenda for the N.I.H.,” he said, “and I think the vast majority of scientists have been reassured by that and have moved on").  And indeed, his friends all assured us when he was appointed that he wouldn't let his religion guide his decisions about science.

Oh, really?  As the story in the New Yorker puts it, the way he made his decision about stem-cell research was to reconcile his views on stem cells with his Christian morality.  He ultimately decided he was in favor of embryonic stem cell research, but not before he wrestled with the decision from his religious point of view.
Before Collins had a direct say in the Administration’s decision on stem cells, he was personally torn by the ethical questions posed by stem-cell research. He has long opposed the creation of embryos for the purpose of research. He sees a human embryo as a potential life, though he thinks that it is not possible scientifically to settle precisely when life begins. But Collins also feels it is morally wasteful not to take advantage of the hundreds of thousands of embryos created for in-vitro fertilization that ultimately are disposed of anyway. These embryos are doomed, but they can help aid disease research.

Although his feelings about embryonic stem-cells are indeed pro-research, and satisfied scientists, particularly those doing stem cell research -- he was quoted as being 'stunned' by the legal decision two weeks ago to halt stem cell research -- it can't be denied that he filtered his thinking through his religious beliefs.  Just as those who were not in favor of his appointment worried that he would do -- and those who supported him assured us he wouldn't.  If he makes the 'right' decision based on his religious views, in the minds of scientists who want to be free to do whatever they want to do, is that now okay?

We all have a moral filter of some sort, and make decisions based on what we think is right and wrong, but one would hope that the head of the organization that guides the direction of research into fundamental life and death matters would have a more nuanced, less superstition-driven basis for those decisions.  Indeed, in his official position, with his hands on so much of the people's money, his decisions should be driven by what would have the greatest impact on the health of the most people.  We trust him when he says that he doesn't believe he has a religious agenda for the NIH, but when his basis for decisions is his evangelical faith, what else can you call it?

And, it must be said that our own primary concern when he was selected to head the NIH had more to do with his genetic and technology fundamentalism than his religion -- a concern that the New Yorker story doesn't acknowledge, though surely we weren't the only scientists who felt this way.  Dr Collins is a technophile's technophile, and there are many reasons to challenge the unrestrained investment in hypertechnologies as the main mission of our national heath institute.

Tuesday, August 10, 2010

Complexity made simply--and reversals, too

A pair of encouraging gene-manipulation stories were reported in the New York Times on Friday (the graphic is from the story).  Essentially, two groups have found ways to de-differentiate specialized cells so that they become able to go down developmental pathways their cellular ancestors did early in the individual's life (or, perhaps, new paths that that cell lineage never took).

Producing various sorts of 'stem' cells is a major goal of modern medicine.  In principle, it will allow the regeneration or even cloning of a patient's damaged organs, with cells from the same individual.  Unlike other therapies, this will not generally lead to tissue rejection (which usually is only of foreign cells), nor will it require removing something, like a ligament, from elsewhere in the patient, to use as a replacement ligament elsewhere in the body.

The problem is that most cells in an adult are fully committed to their current function.  They are functioning stomach, lung, or muscle cells.  As mature differentiated cells they can't do other things, because those require a different set of genes to be activated (or inactivated).  For a muscle cell to be used in lungs its gene expression would have to be that of a cell that lungs use, and that often means of a cell earlier in lung development than the type of cell the therapist needs.

Most vertebrate tissues are made of a series of partly committed stem cells--say, cells in the blood-cell, or lung, or intestinal lineage--that when called upon will differentiate into final functional cells of that organ, known as terminally differentiated cells.  The latter typically can no longer divide.

If organ-specific stem cells can be made more generic, behaving like cells early in the embryonic lineage, or if organ-specific differentiated cells can be made more like that organ's stem cells, then transplanting healthy cells from a patient back into the patient could regenerate healthy tissue to replace damaged tissue.

The studies reported did that in two different contexts.  While still experimental, they're another example of the productive road developmental-genetic research is making possible.  What one group of  investigators did was block the expression of tumor-suppressor genes, which freed the cells to begin to divide.

Finding the right combination of genes to suppress was a critical step in the new research. One of the two tumor suppressor genes is an ancient gene, known as Rb, which is naturally inactivated in newts and fish when they start regenerating tissue. Mammals possess both the Rb gene and a backup, called the Arf gene, which will close down a cancer-prone cell if Rb fails to do so.
The Stanford team found that newts did not have the Arf backup gene, which mammals must have acquired after their lineage diverged from that of amphibians. This suggests that the backup system “evolved at the expense of regeneration,” the Stanford researchers in Friday’s issue of Cell Stem Cell.
The Stanford team shut off both Rb and Arf with a chemical called silencing-RNA and found the mouse muscle cells started dividing. When injected into a mouse’s leg, the cells fused into the existing muscle fibers, just as they are meant to.

The second group of investigators has found a way to transform heart fibroblast cells in a mouse into heart muscle cells, the cells that a heart attack destroys, bypassing the embryonic stem cell stage.

Both of these methods for reprogramming cells reflects something important about life and it was a major topic of the book after which our blog is named.  What it shows is that complex, differentiated tissue is produced by processes of gene expression and response--signaling in generic terms.   Because signaling is a hierarchical process in which response to one signal leads to subsequent signals and response by and between cells, a few changes in signal timing or intensity can lead to complex changes in cell behavior.  Since cells in a tissue communicate to affect their differentiation, simple processes can have what appear to be complex effects:  Complexity made simply.

Understanding this (we think) greatly helps account for the ability of evolution to generate 'complex' traits, the polygenic nature of such traits which might seem antithetical to simplicity, and the  misrepresentation or culpable misunderstanding of the evolution of complexity by the 'Intelligent Design' people.

A few changes in a few processes can make substantial changes in a trait, or evolve some new trait.  Yet many genes are involved in signaling, so that their individual variation can yield trait variation, the kind of small variation GWAS (genomewide association studies) are picking up.  But over long time periods, increasingly complex, integrated traits can arise.

Since signaling interactions are the essence of life, there is every reason to hope that signal manipulation can be a major productive goal of modern medicine, especially regenerative medicine but probably much beyond.  The current articles show steps along that path.

Monday, August 10, 2009

The brain and the braincase, and much more, too

In our book The Mermaid's Tale, we make the point that, in thinking about how the diversity of life arose, people often place too much emphasis on evolutionary time scales compared to the more immediate timescale on which life is actually lived. We note that no two species in nature, no matter how distant or how different their genomes, are any more different than a brain and the braincase that encloses it. Yet the brain and the braincase are made with cells having the same genome, very closely related in terms of cellular descent (from the single fertilized egg), and that in fact interact extensively with each other. This figure, from a simulation done by Brian Lambert, programmer extraordinaire with our group, illustrates how signal interactions among 3 layers, an outer epithelium, a pre-bone layer of mesodermal cells, and an underlying dural layer usually thought of as the outer layer of the brain, produce the different tissues of the brain and skull.

The difference is not in the genomes in any of the cells involved in the development of the head, of course, but in the way their genomes are used. Indeed, in research that we are doing in collaboration with Joan Richtsmeier and others here, and Mimi Jabs at Albert Einstein University in New York, we are finding the intricate way in which these two structures develop through intimate interactions of cell layers that often express similar genes. It is not even clear whether the cells of the future braincase, or those of the future brain, are 'in charge' of this process, and the very concept of a pure hierarchy of control is probably most often a misperception that may derive from our broader culture, in which we do have bosses and the bossed, and natural power hierarchies.

This cooperative kind of interaction based on signaling is essential to life, indeed we would argue that life is signaling. That means that contrary to ideas since Mendel's work on peas was rediscovered in 1900, genes per se are not as much the key to life as gene usage, and also the somewhat Lamarck-like fact that cells, if not organisms, do change--in this case their gene expression and hence their differentiation and behavior, as a result of experience (their cellular context), and these changes are inherited by their descendant cells in the body of the organism.

This is not the place to go on in detail about that--it's a major part of our book. But we are triggered to discuss the subject because a new paper by Dimas et al. in Science Express ("Common Regulatory Variation Impacts Gene Expression in a Cell Type-Dependent Manner", Dimas et al., published in Science Express online, July 30, 2009), has compared regions of the genome in which variation among individuals differently control expression of genes in several different cell lines from the individuals that were tested. The findings are, first, that each cell type has its own regulatory regions distributed across the genome. This is no surprise because each cell, such as different types of blood cells, does different things and must do that via hundreds of different expressed genes. There is variation because these individuals vary, just as you and we do. But the greater variation, as with the brain and the braincase, is among very closely related cells in terms of their gene expression.

Dimas et al. also found that regulatory regions used in only one of the tested cell types tended to cause lower levels of expression, and to be farther from the genes. Why this should be, if it is a finding that holds up in future work, is anyone's guess, but may reflect some aspect of evolution related to the cell type. Another finding was that the great majority, up to around 80%, of regulation is by control elements that only affect one of the tested cell types.

So cells differentiate to make organs, and that's what makes you as an organism. Evolution leads to differences, to be sure, but at least as interesting is the way that cells act as organisms of their own, and evolve--yes, evolve in the true sense of the word--very rapidly and by cooperative communication, rather than competition, among each other. In fact, in the book we call the developmental process of cellular differentiation cytospeciation.

These issues are important far beyond their basic interest. For example, the whole idea of using stem cells to develop replacement tissue as therapy for diseases depends on making the same starting cells become different, a singular challenge. Indeed, it's less of a challenge to produce a whole new animal with stem cells than to direct the differentiation of the cell types needed to make a single organ. But, the more this can be done with the patient's own genome, the more likely it will work.

But, some day it may be possible to take your adult skin cells, and turn them into brain or braincase, to repair damage acquired during life.